Atherogenic lipoprotein phenotype and low-density lipoprotein size and subclasses in patients with growth hormone deficiency before and after short-term replacement therapy

European Journal of Endocrinology

Volumn 156, Issue 3, 2007, Pages 361-367

  Rizzo, Manfredi ^a   Trepp, Roman ^b   Berneis, Kaspar ^c   Christ, Emanuel R ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DYSLIPIDEMIA; FEMALE; GEL ELECTROPHORESIS; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; MALE; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN VARIANT; SHORT COURSE THERAPY; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR I; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 34147115747     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-06-0652     Document Type: Article

References (41)

1. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC & Stewart PM. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001 357 425-431.
2. Rosen T & Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288.
3. Christ ER, Cummings MH, Stolinski M, Jackson N, Lumb PJ, Wierzbicki AS, Sonksen PH, Russell-Jones DL & Umpleby AM. Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study. European Journal of Endocrinology 2006 154 459-466.
4. Christ ER, Cummings MH, Jackson N, Stolinski M, Lumb PJ, Wierzbicki AS, Sönksen PH, Russell-Jones DL & Umpleby AM. Effects of growth hormone (GH) replacement therapy on low-density lipoprotein apolipoprotein B100 kinetics in adult patients with GH deficiency: a stable isotope study. Journal of Clinical Endocrinology and Metabolism 2004 89 1801-1807.
5. de Boer H, Blok GJ, Voerman HJ, Phillips M & Schouten JA. Serum lipid levels in growth hormone-deficient men. Metabolism 1994 43 199-203.
6. Beshyah SA, Shahi M, Skinner E, Sharp P, Foale R & Johnston DG. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. European Journal of Endocrinology 1994 130 451-458.
7. al-Shoumer KA, Anyaoku V, Richmond W & Johnston DG. Elevated leptin concentrations in growth hormone-deficient hypopituitary adults. Clinical Endocrinology 1997 47 153-159.
8. Cummings MH, Christ E, Umpleby AM, Albany E, Wierzbicki A, Lumb PJ, Sonksen PH & Russell-Jones DL. Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1997 82 2010-2013.
9. Rosen T, Eden S, Larson G, Wilhelmsen L & Bengtsson BA. Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinologica 1993 129 195-200.
10. Austin MA, King MC, Vranizan KM & Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990 82 495-506.
11. Krauss RM. Dietary and genetic probes of atherogenic dyslipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 2265-2272.
12. Rizzo M & Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? Journal of Atherosclerosis and Thrombosis 2005 12 237-239.
13. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon Dj, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA & Costa F. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 2735-2752.
14. Sattar N, Petrie JR & jaap Aj. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction. Atherosclerosis 1998 138 229-235.
15. Superko HR. Beyond LDL cholesterol reduction. Circulation 1996 94 2351-2354.
16. Rizzo M & Berneis K. Low-density-lipoproteins size and cardiovascular risk assessment. QJM: an International Journal of Medicine 2006 99 1-14.
17. Packard C, Caslake M & Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. International Journal of Cardiology 2000 74 S17-S22.
18. Berneis KK & Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. Journal of Lipid Research 2002 43 1363-1379.
19. Rizzo M & Berneis K. Should we measure routinely the LDL peak particle size? International Journal of Cardiology 2006 107 147-151.
20. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC & Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. Journal of the American Medical Association 1988 260 1917-1921.
21. Rizzo M, Berneis K, Corrado E & Novo S. The significance of low-density lipoproteins size in vascular diseases. International Angiology 2006 25 4-9.
22. National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002 106 3143-421. (23).
23. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T & Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. Journal of Clinical Endocrinology and Metabolism 1998 83 382-395.
24. Carroll PV, Christ ER, & Sonksen PH. Growth hormone replacement in adults with growth hormone deficiency: assessment of current knowledge. Trends in Endocrinology and Metabolism 2000 11 231-238.
25. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B & Chanson P. Impact of growth hormone treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomised, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism 2004 89 2192-2199.
26. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Growth Hormone Research Society. Growth Hormone and IGF Research 1998 8 89-92.
27. Allain CC, Poon LS, Chan CS, Richmond W & Fu PC. Enzymatic determination of total serum cholesterol. Clinical Chemistry 1974 20 470-475.
28. Nagele U, Hagele EO, Sauer G, Wiedemann E, Lehmann P, Wahlefeldet AW & Gruber W. Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. Journal of Clinical Chemistry and Clinical Biochemistry 1984 22 165-174.
29. Warnick GR, Nguyen T & Albers JJ. Comparison of improved precipitation methods for quantification of high density lipoprotein cholesterol. Clinical Chemistry 1985 31 217-222.
30. Berneis K, Rizzo M, Lazzaroni V, Fruzzetti F & Carmina E. Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2007 92 186-189.
31. Rizzo M, Barbagallo CM, Severino M, Polizzi F, Onorato F, Noto D, Cefalu AB, Pace A, Marino G, Notarbartolo A & Averna RM. Low-density-lipoprotein peak particle size in a Mediterranean population. European Journal of Clinical Investigation 2003 33 126-133.
32. Rizzo M, Taylor JM, Barbagallo CM, Berneis KK, Blanche PJ & Krauss RM. Effects on lipoprotein subclasses of combined expression of human hepatic lipase and human apoB in transgenic rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 141-146.
33. Berneis K, Jeanneret C, Muser J, Felix B & Miserez AR. Low-density lipoprotein size and subclasses are markers of clinically apparent and nonapparent atherosclerosis in type 2 diabetes. Metabolism 2005 54 227-234.
34. Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ & Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. American Journal of Medical Genetics 2001 110 103-110.
35. Berneis KK, Shames DM, Blanche PJ, La Belle M, Rizzo M & Krauss RM. Plasma clearance of human low-density lipoprotein in human apolipoprotein B transgenic mice is related to particle diameter. Metabolism 2004 53 483-487.
36. Rizzo M & Berneis K. Low-density-lipoproteins size and cardiovascular prevention. European Journal of Internal Medicine 2006 17 77-80.
37. Rizzo M & Berneis K. The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovascular Drugs and Therapy 2006 20 205-217.
38. Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson BA, Goth MI, Wilton P & Koltowska-Haggstrorn M. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. European Journal of Endocrinology 2006 155 79-90.
39. Beshyah SA, Henderson A, Niththyananthan R, Skinner E, Anyaoku V, Richmond W, Sharp P & Johnston DG. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. Journal of Clinical Endocrinology and Metabolism 1995 80 356-363.
40. Gola M, Bonadonna S, Doga M & Giustina A. Growth hormone and cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2005 90 1864-1870.
41. Svensson J, Bengtsson BA, Rosen T, Oden A & Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2004 89 3306-3312.